ROR1 and hematologic disorder: [38, 39] Our group has also developed a ROR1 antibody conjugated to MMAE that has been found to be effective in a Richter’s syndrome mouse model [40] and this compound, VLS-101, now zilovertamab vedotin, is under study in hematologic malignancies (NCT03833180) and in solid tumors (NCT04504916).